Table 5.

Engraftment SC vs IV plerixafor

	SC plerixafor 0.24 mg/kg (n = 38)	IV plerixafor 0.32 mg/kg (n = 33)
Infused CD34+ cell dose/kg, mean (range)	3.5 × 106 (1.9-19.7 × 106)	2.9 × 106 (2.0-9.7 × 106)
Patients achieving neutrophil engraftment by day 21, n (%)	37 (97%)	31 (94%)
Median time to neutrophil engraftment, d (range)	10 (5-13)	14 (11-27)*,†
Patients achieving platelet engraftment by day 30, n (%)	36 (95%)	23 (70%)†
Median time to platelet engraftment, d (range)	22 (8-102)	25 (15-219)†
100% donor chimerism by day 100	MA: 100%	MA: 94% (31/33)
	RIC: N/A	RIC: 40% (2/5)

MA, myeloablative.

^*P < .05.

^†GVHD prophylaxis included methotrexate, which was not included in the SC plerixafor group.